Table 3.

Psychiatric assessments and hormone levels.

	Testosterone				Placebo				P-value*
	Baseline		8 Weeks		Baseline		8 Weeks
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Depression Symptom Severity
MADRS Score	26.8	6.3	15.3	9.6	26.3	5.4	14.4	9.3	0.91
CGI-S Score	4.3	0.6	3.1	1.4	4.3	0.6	2.8	1.2	0.78
IDS-SR	35.9	10.5	20.1	11.2	34.9	10.0	19.1	10.1	0.81
Fatigue and Sleepiness
BFI	6.2	1.9	4.0	2.3	5.6	2.0	3.7	2.8	0.92
ESS	8.0	4.7	6.0	4.2	9.4	4.7	6.8	3.6	0.80
FSS	45.0	12.5	38.6	13.8	42.4	12.3	35.9	13.9	0.81
Sexual Function
DISF	32.8	27.3	45.1	31.3	38.7	30.1	47.5	34.0	0.37
Quality of Life
SF-36 PCS	66.7	20.3	72.6	19.6	66.7	20.6	74.3	18.3	0.43
SF-36 MCS	29.5	13	54.5	22.4	33.1	14.5	54.5	19.7	0.27
Hormone Levels
Total testosterone	19	11	105	70	18	9	18	10	p<0.0001
Free testosterone	0.3	0.2	1.9	1.1	0.3	0.2	0.4	0.2	p<0.001

^*P -value for comparison of change in psychiatric assessment or hormone level from baseline to 8 weeks in subjects randomized to receive testosterone vs placebo. For SF-36, lower scores indicate worse quality of life. For DISF, lower scores indicate worse sexual function. For all other scales/questionnaires, higher scores indicate worse symptom severity. Abbreviations: MADRS: Montgomery-Asberg Depression Rating Scale; CGI-S: Clinician Global Impressions-Severity Scale; IDS-SR: Inventory of Depressive Symptomology-Self-Report; BFI: Brief Fatigue Inventory; ESS: Epworth Sleepiness Scale; FSS: Fatigue Severity Scale; DISF: Derogatis Interview for Sexual Function; SF-36 PCS: Short Form-36 Physical Component Score; SF-36 MCS: Short Form-36 Mental Component Score.